Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome

G. Hacohen-Kleiman, S. Sragovich, G. Karmon, AYL. Gao, I. Grigg, M. Pasmanik-Chor, A. Le, V. Korenková, RA. McKinney, I. Gozes,

. 2018 ; 128 (11) : 4956-4969. [pub] 20180924

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S., audiovizuální média

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035071

Previous findings showed that in mice, complete knockout of activity-dependent neuroprotective protein (ADNP) abolishes brain formation, while haploinsufficiency (Adnp+/-) causes cognitive impairments. We hypothesized that mutations in ADNP lead to a developmental/autistic syndrome in children. Indeed, recent phenotypic characterization of children harboring ADNP mutations (ADNP syndrome children) revealed global developmental delays and intellectual disabilities, including speech and motor dysfunctions. Mechanistically, ADNP includes a SIP motif embedded in the ADNP-derived snippet drug candidate NAP (NAPVSIPQ, also known as CP201), which binds to microtubule end-binding protein 3, essential for dendritic spine formation. Here, we established a unique neuronal membrane-tagged, GFP-expressing Adnp+/- mouse line allowing in vivo synaptic pathology quantification. We discovered that Adnp deficiency reduced dendritic spine density and altered synaptic gene expression, both of which were partly ameliorated by NAP treatment. Adnp+/-mice further exhibited global developmental delays, vocalization impediments, gait and motor dysfunctions, and social and object memory impairments, all of which were partially reversed by daily NAP administration (systemic/nasal). In conclusion, we have connected ADNP-related synaptic pathology to developmental and behavioral outcomes, establishing NAP in vivo target engagement and identifying potential biomarkers. Together, these studies pave a path toward the clinical development of NAP (CP201) for the treatment of ADNP syndrome.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035071
003      
CZ-PrNML
005      
20191017092052.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1172/JCI98199 $2 doi
035    __
$a (PubMed)30106381
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hacohen-Kleiman, Gal $u The Lily and Avraham Gildor Chair for the Investigation of Growth Factors; The Elton Laboratory for Neuroendocrinology; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv, Israel.
245    10
$a Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome / $c G. Hacohen-Kleiman, S. Sragovich, G. Karmon, AYL. Gao, I. Grigg, M. Pasmanik-Chor, A. Le, V. Korenková, RA. McKinney, I. Gozes,
520    9_
$a Previous findings showed that in mice, complete knockout of activity-dependent neuroprotective protein (ADNP) abolishes brain formation, while haploinsufficiency (Adnp+/-) causes cognitive impairments. We hypothesized that mutations in ADNP lead to a developmental/autistic syndrome in children. Indeed, recent phenotypic characterization of children harboring ADNP mutations (ADNP syndrome children) revealed global developmental delays and intellectual disabilities, including speech and motor dysfunctions. Mechanistically, ADNP includes a SIP motif embedded in the ADNP-derived snippet drug candidate NAP (NAPVSIPQ, also known as CP201), which binds to microtubule end-binding protein 3, essential for dendritic spine formation. Here, we established a unique neuronal membrane-tagged, GFP-expressing Adnp+/- mouse line allowing in vivo synaptic pathology quantification. We discovered that Adnp deficiency reduced dendritic spine density and altered synaptic gene expression, both of which were partly ameliorated by NAP treatment. Adnp+/-mice further exhibited global developmental delays, vocalization impediments, gait and motor dysfunctions, and social and object memory impairments, all of which were partially reversed by daily NAP administration (systemic/nasal). In conclusion, we have connected ADNP-related synaptic pathology to developmental and behavioral outcomes, establishing NAP in vivo target engagement and identifying potential biomarkers. Together, these studies pave a path toward the clinical development of NAP (CP201) for the treatment of ADNP syndrome.
650    _2
$a aminokyselinové motivy $7 D020816
650    _2
$a zvířata $7 D000818
650    _2
$a autistická porucha $x genetika $x metabolismus $x patologie $x patofyziologie $7 D001321
650    _2
$a chování zvířat $7 D001522
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a buněčná membrána $x genetika $x metabolismus $x patologie $7 D002462
650    _2
$a dendritické trny $x metabolismus $x patologie $7 D049229
650    _2
$a regulace genové exprese $7 D005786
650    _2
$a homeodoménové proteiny $7 D018398
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myši knockoutované $7 D018345
650    _2
$a mikrotubuly $x genetika $x metabolismus $x patologie $7 D008870
650    12
$a modely neurologické $7 D008959
650    _2
$a mutace $7 D009154
650    _2
$a naftochinony $x farmakologie $7 D009285
650    _2
$a proteiny nervové tkáně $x nedostatek $7 D009419
650    _2
$a synapse $x metabolismus $x patologie $7 D013569
650    _2
$a syndrom $7 D013577
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
655    _2
$a audiovizuální média $7 D059040
700    1_
$a Sragovich, Shlomo $u The Lily and Avraham Gildor Chair for the Investigation of Growth Factors; The Elton Laboratory for Neuroendocrinology; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Karmon, Gidon $u The Lily and Avraham Gildor Chair for the Investigation of Growth Factors; The Elton Laboratory for Neuroendocrinology; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Gao, Andy Y L $u Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
700    1_
$a Grigg, Iris $u The Lily and Avraham Gildor Chair for the Investigation of Growth Factors; The Elton Laboratory for Neuroendocrinology; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Pasmanik-Chor, Metsada $u Bioinformatics Unit, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Le, Albert $u Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
700    1_
$a Korenková, Vlasta $u BIOCEV, Institute of Biotechnology CAS, Vestec, Czech Republic.
700    1_
$a McKinney, R Anne $u Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
700    1_
$a Gozes, Illana $u The Lily and Avraham Gildor Chair for the Investigation of Growth Factors; The Elton Laboratory for Neuroendocrinology; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv, Israel.
773    0_
$w MED00002590 $t The Journal of clinical investigation $x 1558-8238 $g Roč. 128, č. 11 (2018), s. 4956-4969
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30106381 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191017092520 $b ABA008
999    __
$a ok $b bmc $g 1451731 $s 1073621
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 128 $c 11 $d 4956-4969 $e 20180924 $i 1558-8238 $m The Journal of clinical investigation $n J Clin Invest $x MED00002590
LZP    __
$a Pubmed-20191007
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace